| Barchart Demo Center |
$1,5800
+0,1400 (+9,72%)
en date du mai 31, 2024
en date du mai 31, 2024
| Dernière | 1,5800 |
|---|---|
| Variation | +0,1400 (+9,72%) |
| Ouverture | 1,4400 |
| Clôture précédente | 1,4400 |
| Écart (actuel) |
1,4400
1,6698
|
| Écart 52 semaines |
1,2600
17,1700
|
| Volume | 93 300 |
| Volume Moyen | 159 950 |
| Secteur | SIC-2834 Pharmaceutical Preparations |
Perfomance Comparison
| Nom | Aujourd'hui | 3-mois | 1 an |
|---|---|---|---|
| AEON |
 +9,72% |
 -87,45% |
 -84,78% |
| DJIA |
 +1,51% |
-2,09% |
+16,90% |
| S&P 500 |
+0,80% |
+1,01% |
+25,49% |
Statistiques clef
| BPA Annuel | N/A |
|---|---|
| Rendement dividendes | 0,00% |
| Rapport Prix/Bénéfices | N/A |
| Market Capitalization, $K | 58 680 |
| Alpha pondéré | -36,24 |
| Écart-type | +0,53 |
| Marge d'exploitation | N/A |
| Beta | 0,7700 |
Taux de croissance
| Cette année | -78,06% | |||
| 1 An(s) | -84,85% | |||
| 3 An(s) | -83,74% |
Opinion
| Vendre | Conserver | Acheter |
Articles récents
AEON Biopharma Reports First Quarter 2024 Financial
GlobeNewswire - Tue May 14, 03:05PM CDT
– Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints – –...(version intégrale)
AEON: 1,5800 (+0,1400)
AEON Biopharma Announces Preliminary Top-Line Results
GlobeNewswire - Fri May 03, 06:00AM CDT
– Trial did not meet primary endpoint –...(version intégrale)
AEON: 1,5800 (+0,1400)
CORRECTION -- AEON Biopharma Announces Redemption of
GlobeNewswire - Sat Mar 30, 09:53PM CDT
IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Regarding a release issued under the same headline on March 29, 2024 by AEON Biopharma, Inc. (NYSE:...(version intégrale)
AEON: 1,5800 (+0,1400)
AEON Biopharma Announces Redemption of Public Warrants
GlobeNewswire - Fri Mar 29, 03:15PM CDT
IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Company”), a clinical-stage...(version intégrale)
AEON: 1,5800 (+0,1400)
AEON Biopharma Reports Fourth Quarter and Full Year
GlobeNewswire - Fri Mar 29, 02:45PM CDT
– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive...(version intégrale)
AEON: 1,5800 (+0,1400)